Open AccessComparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry
Author(s) -
Michael A. Überall,
Ute Essner,
Carlos Vila Silván,
G. Mueller-Schwefe
Publication year - 2022
Publication title -
journal of pain research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.888
H-Index - 49
ISSN - 1178-7090
DOI - 10.2147/jpr.s340968
Subject(s) - medicine , tolerability , dronabinol , discontinuation , neuropathic pain , adverse effect , confidence interval , anesthesia , cannabidiol , placebo , randomized controlled trial , clinical trial , cannabis , cannabinoid , receptor , alternative medicine , pathology , psychiatry
To compare the effectiveness and tolerability of add-on treatment with nabiximols (NBX: delta-9-tetrahydrocannabinol: cannabidiol) oromucosal spray or oral dronabinol (DRO: synthetic tetrahydrocannabinol) in patients with severe neuropathic pain poorly responsive to established treatments.